Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 4/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 2/20 | 0.43 |
| ▸ | UBE2M | P61081 | 5/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781273 | 0.83 | RHOC (0.40) | TEAD1UBE2MDCUN1D1 | |
| SCHEMBL24780794 | 0.80 | TEAD1 (0.41) | TEAD1UBE2MDCUN1D1 | |
| SCHEMBL21856317 | 0.80 | IDH2 (0.43) | TEAD1PHGDHIDH2MLNRUBE2M | |
| SCHEMBL21957254 | 0.78 | TEAD1 (0.71) | TEAD1PHGDHMLNRDCUN1D1EPHX2 | |
| SCHEMBL21958163 | 0.78 | TEAD1 (0.71) | TEAD1PHGDHMLNRDCUN1D1EPHX2 | |
| SCHEMBL24780719 | 0.78 | TEAD1 (0.71) | TEAD1PHGDHMLNRDCUN1D1EPHX2 | |
| SCHEMBL24781281 | 0.75 | IDH2 (0.62) | PHGDHIDH2MLNRUBE2MDCUN1D1 | |
| SCHEMBL24781034 | 0.75 | IDH2 (0.50) | TEAD1PHGDHIDH2MLNRUBE2M | |
| SCHEMBL21959807 | 0.75 | IDH2 (0.47) | TEAD1PHGDHIDH2MLNRUBE2M | |
| SCHEMBL24781276 | 0.75 | DCUN1D1 (0.41) | TEAD1MLNRUBE2MDCUN1D1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885PHGDH 2187/4885IDH2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.